Stocksigma LogoStocksigma Logo

Venmax Drugs Reports Nil Deviation in Preferential Issue Fund Utilization

Venmax Drugs and Pharmaceuticals confirmed zero deviation in the utilization of proceeds raised via fully convertible equity warrants on a preferential

Venmax Drugs Reports Nil Deviation in Preferential Issue Fund Utilization

Venmax Drugs and Pharmaceuticals Ltd 路 Others (Uncategorized) 路 12 Nov 2026, 10:34 pm

Venmax Drugs Reports Nil Deviation in Preferential Issue Fund Utilization Venmax Drugs and Pharmaceuticals confirmed zero deviation in the utilization of proceeds raised via fully convertible equity warrants on a preferential basis for the quarter ended 30th Sep'26. Out of the planned Rs. 20.05 crore fundraise initiated on 20th Mar'25, the company has raised Rs. 18.49 crore through 92,44,999 warrant conversions. As of 30th Sep'26, funds deployed include Rs. 8.44 crore toward working capital (out of Rs. 10.00 crore allocated) and the entire Rs. 10.05 crore toward general corporate purposes and business acquisitions.

Original exchange filing (PDF)

More announcements from Venmax Drugs and Pharmaceuticals Ltd

All Venmax Drugs and Pharmaceuticals Ltd announcements